Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study

Jaana T. Joensuu, Kalle J. Aaltonen, Pasi Aronen, Tuulikki Sokka, Kari Puolakka, Riitta Tuompo, Markku Korpela, Mikko Vasala, Kirsti Ilva, Dan Nordström, Marja Blom

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalRheumatology
Volume55
Issue number10
Pages (from-to)1803-1811
Number of pages9
ISSN1462-0324
DOIs
Publication statusPublished - Oct 2016
MoE publication typeA1 Journal article-refereed

Fields of Science

  • cost-effectiveness
  • rheumatoid arthritis
  • biological DMARDs
  • observational study
  • EULAR RECOMMENDATIONS
  • ECONOMIC-EVALUATION
  • CLINICAL-PRACTICE
  • INFLIXIMAB
  • TRIALS
  • MANAGEMENT
  • TNF
  • ETANERCEPT
  • ADALIMUMAB
  • INHIBITORS
  • 317 Pharmacy

Cite this